SS Innovations International Inc. Common Stock (SSII)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

SS Innovations is a commercial-stage surgical robotics company selling the SSi Mantra system and instruments. Revenue is moving in the right direction: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $13.9M, up from $10.0M in fiscal Q2 2025, and FY2025 revenue was $42.5M versus $20.6M in FY2024 and $5.9M in FY2023. That is real adoption. But the bottom line is poor. FY2025 net income was -$12.1M, FY2024 -$19.2M, FY2023 -$20.9M; in fiscal Q2 2026, net income was -$2.7M and diluted EPS -$0.01. TTM free cash flow is -$18.2M, so growth consumes cash. FairStock's calculations show a P/E of -42.50 and P/B of 9.44 at the 2026-10-13 close of $2.55, ROE of -26.06%, ROCE of -6.34%, Piotroski 3/9, and FCF yield -3.6%. The balance sheet has D/E of 0.33 and Altman Z-Score 6.70, so leverage is not the immediate problem, but persistent losses and high book multiple are. FairStock Score 44/100 and Lynch category none—loss in each of last four years—fit my view: this is not a Graham bargain. A wide moat is not visible in the numbers; it will need to prove pricing power, margins, and cash generation. At $2.55, the market cap is $511M, which prices in a lot of future success relative to today's losses. I prefer waiting for evidence of sustainable profits before calling it cheap.

In plain English: SS Innovations makes robotic surgical systems and tools, mainly for hospitals in India and other markets. Revenue is growing quickly, but the company still loses money and has not made a profit in the last four years. At $2.55 a share, the price is near the low end of its 52-week range, but it still looks expensive compared with its assets and profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K/A (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer